Daiichi Sankyo has announced the dosage of the first subject in the randomised Phase III QuANTUM-Wild trial of oral Vanflyta ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...

Moleculin Biotech shares are trading higher on Wednesday after the company announced the online publication of preclinical ...

The world's oceans represent a vast and largely untapped source of biodiversity, offering a high probability for the ...

The first patient has been dosed in the QuANTUM-Wild phase 3 trial evaluating Daiichi Sankyo’s (TSE: 4568) VANFLYTA® ...

(RTTNews) - Moleculin Biotech, Inc. (MBRX), Wednesday announced the preliminary activity of Annamycin in heavily pretreated, relapsed/refractory acute myeloid leukemia or AML patients who had ...

Phase 2 data show about half of patients with high-risk or secondary acute myeloid leukemia achieved a complete response or ...

Triplet induction with alternating consolidation regimens appeared to be effective in patients with newly diagnosed AML, according to researchers.

Patients received induction chemotherapy with oblimersen, cytarabine and daunorubicin. Further doses of oblimersen and high-dose cytarabine were administered as consolidation treatment in the ...

She initially received oral tretinoin (Vesanoid) followed by daunorubicin on days 1 through 3 and cytarabine on days 1 to 5 (planned treatment is to receive cytarabine for 2 more doses).